Serum FGF-23 and α-Klotho Levels in Prolactinoma and Non-Tumoral Hyperprolactinemia: An Exploratory Cross-Sectional Comparative Study
Diagnostics · 22.07.2026 · 16 (14) · 2298
DOI: 10.3390/diagnostics16142298 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift Diagnostics, online erschienen am 22.07.2026. Verfasst von Abdullah Altuğ und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Faculty of Medicine, Fırat University, Elazığ 23119, Türkiye. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: This study aimed to evaluate serum fibroblast growth factor-23 (FGF-23) and α-Klotho levels in patients with prolactinoma and patients with non-tumoral hyperprolactinemia and to explore their discriminatory performance for prolactinoma.
Methods
Seventy-three participants were included in this single-center, cross-sectional comparative study: non-tumoral hyperprolactinemia (n = 14), prolactinoma (n = 29), and healthy controls (n = 30). All patients with prolactinoma had received dopamine agonist therapy for at least six months. Serum FGF-23 and α-Klotho were measured by ELISA, and between-group comparisons, correlation analyses, linear regression analyses, and receiver operating characteristic (ROC) analyses were performed.
Results
FGF-23 concentrations differed significantly among the groups (overall p < 0.001). Post hoc analysis showed that FGF-23 concentrations were significantly higher in the prolactinoma group [236.10 (107.70–667.90) pg/mL] than in healthy controls [138.75 (49.40–253.60) pg/mL] (adjusted p < 0.001), whereas the difference between the prolactinoma and non-tumoral hyperprolactinemia groups [166.20 (100.30–327.20) pg/mL] was not statistically significant (adjusted p = 0.075). α-Klotho concentrations were significantly higher in the prolactinoma group [2.908 (1.376–6.257) ng/mL] than in both the non-tumoral hyperprolactinemia group [2.244 (1.432–5.139) ng/mL] (adjusted p = 0.038) and healthy controls [2.204 (0.149–4.917) ng/mL] (adjusted p < 0.001). In pooled analyses, both biomarkers showed positive correlations with prolactin and weak negative correlations with hemoglobin. However, prolactin and hemoglobin were not independently associated with either biomarker after multivariable adjustment. The non-tumoral hyperprolactinemia group did not differ significantly from healthy controls for either biomarker. For distinguishing prolactinoma from non-tumoral hyperprolactinemia, the AUCs were 0.741 for FGF-23, 0.732 for α-Klotho, and 0.862 for the exploratory combined model.
Conclusions
Dopamine agonist-treated prolactinoma was characterized by higher circulating FGF-23 concentrations than those in healthy controls and by higher α-Klotho concentrations than those in both healthy controls and patients with non-tumoral hyperprolactinemia. Exploratory ROC analyses suggested moderate discriminatory performance for the individual biomarkers and higher apparent performance for the combined model; however, these findings should be interpreted cautiously and require validation in larger, treatment-naïve cohorts.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Faculty of Medicine, Fırat University, Elazığ 23119, Türkiye.
- Department of Biochemistry, Faculty of Medicine, Fırat University, Elazığ 23119, Türkiye.
- Department of Endocrinology, Faculty of Medicine, Fırat University, Elazığ 23119, Türkiye.
ORCID-Profile: Abdullah Altuğ, Mithat Mızrak, Emir Dönder
Zitieren
APA
Altuğ, A., Yıldırım Arı, F. Z., Mızrak, M., Gürsu, M. F., Kaymaz, T., Dönder, E., & Yılmaz, A. (2026). Serum FGF-23 and α-Klotho Levels in Prolactinoma and Non-Tumoral Hyperprolactinemia: An Exploratory Cross-Sectional Comparative Study. Diagnostics, 16(14), 2298. https://doi.org/10.3390/diagnostics16142298
Vancouver
Altuğ A, Yıldırım Arı FZ, Mızrak M, Gürsu MF, Kaymaz T, Dönder E, et al. Serum FGF-23 and α-Klotho Levels in Prolactinoma and Non-Tumoral Hyperprolactinemia: An Exploratory Cross-Sectional Comparative Study. Diagnostics. 2026;16(14):2298. doi:10.3390/diagnostics16142298
BibTeX
@article{Altu2026,
author = {Altuğ, Abdullah and Yıldırım Arı, Fatma Zehra and Mızrak, Mithat and Gürsu, Mehmet Ferit and Kaymaz, Tuğçe and Dönder, Emir and Yılmaz, Ahmet},
title = {Serum FGF-23 and α-Klotho Levels in Prolactinoma and Non-Tumoral Hyperprolactinemia: An Exploratory Cross-Sectional Comparative Study},
journal = {Diagnostics},
year = {2026},
volume = {16},
number = {14},
pages = {2298},
doi = {10.3390/diagnostics16142298}
}
EUVIMED